A phenomenological investigation into the lived experience of ibogaine and its potential to treat opioid use disorders

Introduction

Ibogaine is a naturally occurring indole alkaloid from Tabernanthe iboga that has attracted attention for its putative capacity to reduce opioid withdrawal and craving. The Introduction frames opioid dependence as a major public-health problem in the United States and notes preclinical and early clinical signals of ibogaine's anti-addictive effects, including rodent studies showing reduced withdrawal and self-administration and the proposed action of its metabolite noribogaine on neural circuitry implicated in addiction. The authors also highlight important safety concerns (including temporally associated deaths and gaps in safety data) and the practical reality that much ibogaine treatment has occurred outside regulated clinical trials. Camlin and colleagues set out to deepen understanding of the subjective, lived ibogaine experience among people who sought treatment for opioid use disorders. Using a phenomenological qualitative approach, the study aimed to identify common experiential themes (neurological/physical effects, sensory/visionary phenomena, effects on withdrawal and craving, and shifts in outlook) that might inform development of standardised treatment protocols and post‑treatment integration strategies.